FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197973059> ?p ?o ?g. }

• W3197973059 endingPage "1864.e10" @default.
• W3197973059 startingPage "1853" @default.
• W3197973059 abstract "Background & AimsOral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC).MethodsIn vitro studies measured binding properties of PTG-100. Mouse studies measured biomarkers and drug concentrations in blood and tissues. The phase 1 study involved healthy volunteers. In phase 2a, patients with moderate to severe active UC were randomized to receive PTG-100 (150, 300, or 900 mg) or placebo once daily for 12-weeks.ResultsPTG-100 potently and selectively blocks α4β7. Oral dosing of PTG-100 in mice showed high levels of target engagement and exposure in gut-associated lymphoid tissues. In healthy volunteers, PTG-100 showed dose-dependent increases in plasma exposure and blood target engagement. Although this phase 2a study initially did not meet the primary endpoint, a blinded reread of the endoscopy videos by a third party indicated clinical efficacy in conjunction with histologic remission at doses correlating with less than 100% receptor occupancy in peripheral blood.ConclusionsPTG-100 showed local gastrointestinal tissue target engagement and inhibition of memory T-cell trafficking in mice. It was safe and well tolerated in phase 1 and 2 studies. Phase 2a data are consistent with biological and clinical response and showed a dose response reflecting similar activities in preclinical models and healthy individuals. These data suggest that local gut activity of an oral α4β7 integrin antagonist, distinct from full target engagement in blood, are important for efficacy and the treatment of UC. (ClinicalTrials.gov, Number NCT02895100; EudraCT, Number 2016-003452-75) Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC). In vitro studies measured binding properties of PTG-100. Mouse studies measured biomarkers and drug concentrations in blood and tissues. The phase 1 study involved healthy volunteers. In phase 2a, patients with moderate to severe active UC were randomized to receive PTG-100 (150, 300, or 900 mg) or placebo once daily for 12-weeks. PTG-100 potently and selectively blocks α4β7. Oral dosing of PTG-100 in mice showed high levels of target engagement and exposure in gut-associated lymphoid tissues. In healthy volunteers, PTG-100 showed dose-dependent increases in plasma exposure and blood target engagement. Although this phase 2a study initially did not meet the primary endpoint, a blinded reread of the endoscopy videos by a third party indicated clinical efficacy in conjunction with histologic remission at doses correlating with less than 100% receptor occupancy in peripheral blood. PTG-100 showed local gastrointestinal tissue target engagement and inhibition of memory T-cell trafficking in mice. It was safe and well tolerated in phase 1 and 2 studies. Phase 2a data are consistent with biological and clinical response and showed a dose response reflecting similar activities in preclinical models and healthy individuals. These data suggest that local gut activity of an oral α4β7 integrin antagonist, distinct from full target engagement in blood, are important for efficacy and the treatment of UC. (ClinicalTrials.gov, Number NCT02895100; EudraCT, Number 2016-003452-75)" @default.
• W3197973059 created "2021-09-13" @default.
• W3197973059 creator A5003510725 @default.
• W3197973059 creator A5010324654 @default.
• W3197973059 creator A5017839485 @default.
• W3197973059 creator A5018781693 @default.
• W3197973059 creator A5026638199 @default.
• W3197973059 creator A5032150391 @default.
• W3197973059 creator A5038140363 @default.
• W3197973059 creator A5048464948 @default.
• W3197973059 creator A5053975805 @default.
• W3197973059 creator A5057225122 @default.
• W3197973059 creator A5057433933 @default.
• W3197973059 creator A5057899912 @default.
• W3197973059 creator A5059435501 @default.
• W3197973059 creator A5062818239 @default.
• W3197973059 creator A5066649201 @default.
• W3197973059 creator A5076006832 @default.
• W3197973059 date "2021-12-01" @default.
• W3197973059 modified "2023-10-17" @default.
• W3197973059 title "PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis" @default.
• W3197973059 cites W1619160309 @default.
• W3197973059 cites W1986834440 @default.
• W3197973059 cites W2000069945 @default.
• W3197973059 cites W2031551895 @default.
• W3197973059 cites W2077531651 @default.
• W3197973059 cites W2109683366 @default.
• W3197973059 cites W2160619682 @default.
• W3197973059 cites W2162805528 @default.
• W3197973059 cites W2165290386 @default.
• W3197973059 cites W2346478945 @default.
• W3197973059 cites W2583464358 @default.
• W3197973059 cites W2611548364 @default.
• W3197973059 cites W2615644319 @default.
• W3197973059 cites W2616235887 @default.
• W3197973059 cites W2773289068 @default.
• W3197973059 cites W2791118194 @default.
• W3197973059 cites W2885705898 @default.
• W3197973059 cites W2888572800 @default.
• W3197973059 cites W2944246085 @default.
• W3197973059 cites W2945386610 @default.
• W3197973059 cites W2979752476 @default.
• W3197973059 cites W3027455289 @default.
• W3197973059 cites W4296224660 @default.
• W3197973059 doi "https://doi.org/10.1053/j.gastro.2021.08.045" @default.
• W3197973059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34474038" @default.
• W3197973059 hasPublicationYear "2021" @default.
• W3197973059 type Work @default.
• W3197973059 sameAs 3197973059 @default.
• W3197973059 citedByCount "19" @default.
• W3197973059 countsByYear W31979730592021 @default.
• W3197973059 countsByYear W31979730592022 @default.
• W3197973059 countsByYear W31979730592023 @default.
• W3197973059 crossrefType "journal-article" @default.
• W3197973059 hasAuthorship W3197973059A5003510725 @default.
• W3197973059 hasAuthorship W3197973059A5010324654 @default.
• W3197973059 hasAuthorship W3197973059A5017839485 @default.
• W3197973059 hasAuthorship W3197973059A5018781693 @default.
• W3197973059 hasAuthorship W3197973059A5026638199 @default.
• W3197973059 hasAuthorship W3197973059A5032150391 @default.
• W3197973059 hasAuthorship W3197973059A5038140363 @default.
• W3197973059 hasAuthorship W3197973059A5048464948 @default.
• W3197973059 hasAuthorship W3197973059A5053975805 @default.
• W3197973059 hasAuthorship W3197973059A5057225122 @default.
• W3197973059 hasAuthorship W3197973059A5057433933 @default.
• W3197973059 hasAuthorship W3197973059A5057899912 @default.
• W3197973059 hasAuthorship W3197973059A5059435501 @default.
• W3197973059 hasAuthorship W3197973059A5062818239 @default.
• W3197973059 hasAuthorship W3197973059A5066649201 @default.
• W3197973059 hasAuthorship W3197973059A5076006832 @default.
• W3197973059 hasBestOaLocation W31979730591 @default.
• W3197973059 hasConcept C111113717 @default.
• W3197973059 hasConcept C112705442 @default.
• W3197973059 hasConcept C126322002 @default.
• W3197973059 hasConcept C142724271 @default.
• W3197973059 hasConcept C170493617 @default.
• W3197973059 hasConcept C203092338 @default.
• W3197973059 hasConcept C204787440 @default.
• W3197973059 hasConcept C27081682 @default.
• W3197973059 hasConcept C2775862500 @default.
• W3197973059 hasConcept C2776885963 @default.
• W3197973059 hasConcept C2777056448 @default.
• W3197973059 hasConcept C2777288759 @default.
• W3197973059 hasConcept C2779134260 @default.
• W3197973059 hasConcept C2780479503 @default.
• W3197973059 hasConcept C31760486 @default.
• W3197973059 hasConcept C535046627 @default.
• W3197973059 hasConcept C71924100 @default.
• W3197973059 hasConcept C90924648 @default.
• W3197973059 hasConcept C98274493 @default.
• W3197973059 hasConceptScore W3197973059C111113717 @default.
• W3197973059 hasConceptScore W3197973059C112705442 @default.
• W3197973059 hasConceptScore W3197973059C126322002 @default.
• W3197973059 hasConceptScore W3197973059C142724271 @default.
• W3197973059 hasConceptScore W3197973059C170493617 @default.
• W3197973059 hasConceptScore W3197973059C203092338 @default.
• W3197973059 hasConceptScore W3197973059C204787440 @default.
• W3197973059 hasConceptScore W3197973059C27081682 @default.

• next